celecoxib has been researched along with Schistosomiasis mansoni in 2 studies
Schistosomiasis mansoni: Schistosomiasis caused by Schistosoma mansoni. It is endemic in Africa, the Middle East, South America, and the Caribbean and affects mainly the bowel, spleen, and liver.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present study evaluated the effect of oral administration of five days celecoxib regimen (20 mg/kg/day) against different developmental stages of Schistosoma mansoni infection." | 8.02 | Effect of celecoxib against different developmental stages of experimental Schistosoma mansoni infection. ( Abou-El-Naga, IF; El-Temsahy, MM; Ibrahim, EI; Makled, S; Mogahed, NMFH; Sheta, E, 2021) |
| " The latter enhance the solubility, bioavailability and drug delivery and hence can decrease the frequency of administration which is of great clinical value." | 5.72 | A single oral dose of celecoxib-loaded solid lipid nanoparticles for treatment of different developmental stages of experimental schistosomiasis mansoni. ( Abou-El-Naga, IF; El-Temsahy, MM; Elsawy, ESA; Ibrahim, EI; Makled, S; Mogahed, NMFH, 2022) |
| " The present study evaluated the effect of oral administration of five days celecoxib regimen (20 mg/kg/day) against different developmental stages of Schistosoma mansoni infection." | 4.02 | Effect of celecoxib against different developmental stages of experimental Schistosoma mansoni infection. ( Abou-El-Naga, IF; El-Temsahy, MM; Ibrahim, EI; Makled, S; Mogahed, NMFH; Sheta, E, 2021) |
| " The latter enhance the solubility, bioavailability and drug delivery and hence can decrease the frequency of administration which is of great clinical value." | 1.72 | A single oral dose of celecoxib-loaded solid lipid nanoparticles for treatment of different developmental stages of experimental schistosomiasis mansoni. ( Abou-El-Naga, IF; El-Temsahy, MM; Elsawy, ESA; Ibrahim, EI; Makled, S; Mogahed, NMFH, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, EI | 2 |
| Abou-El-Naga, IF | 2 |
| El-Temsahy, MM | 2 |
| Elsawy, ESA | 1 |
| Makled, S | 2 |
| Mogahed, NMFH | 2 |
| Sheta, E | 1 |
2 other studies available for celecoxib and Schistosomiasis mansoni
| Article | Year |
|---|---|
A single oral dose of celecoxib-loaded solid lipid nanoparticles for treatment of different developmental stages of experimental schistosomiasis mansoni.
Topics: Animals; Celecoxib; Liposomes; Mice; Nanoparticles; Schistosoma mansoni; Schistosomiasis mansoni | 2022 |
Effect of celecoxib against different developmental stages of experimental Schistosoma mansoni infection.
Topics: Administration, Oral; Animals; Anthelmintics; Apoptosis; Celecoxib; Disease Models, Animal; Female; | 2021 |